Inhaled treprostinil for COPD with low oxygen
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests an inhaled medication called treprostinil (Tyvaso) to see if it can help people with COPD who have low blood oxygen levels. You may qualify if you have chronic bronchitis, use oxygen at rest or during exercise, and meet specific lung function criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years of age or older.
- You have chronic bronchitis (a cough with mucus most days for at least 3 months in two years).
- You are a current or former smoker with at least 20 pack-years of smoking history.
- You have COPD confirmed by lung function tests, with moderate to severe airflow limitation.
- You use supplemental oxygen at rest or during exercise (up to 4 liters per minute).
- You are on stable COPD medications (no changes in the last 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an inhaled medication called treprostinil (which helps open blood vessels in the lungs) can improve exercise ability in people who get high blood pressure in the lungs only during exercise. Participation involves taking the medication and doing exercise tests to see how well you do.
This trial tests an inhaled medication called treprostinil palmitil to see if it can slow the decline of lung function in people with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. It's for people whose lung disease is getting worse despite standard care, and it may help preserve their breathing ability.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
Hear when a new Hypoxemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.